Theravance Q1 2023 Earnings Report

Theravance Biopharma reported first quarter 2023 financial results, with YUPELRI retail new patient starts growing and a Phase 3 study for ampreloxetine initiated.

Key Takeaways

Theravance Biopharma reported first quarter 2023 financial results, highlighting a focus on commercial and development efforts. YUPELRI retail new patient starts grew by 61% and the company initiated enrollment for the CYPRESS Phase 3 study for ampreloxetine.

YUPELRI retail new patient starts grew by 61% and achieved a sixth consecutive quarter of record highs.

Initiated enrollment for CYPRESS, the Phase 3 study for ampreloxetine.

The company is positioned to drive an acceleration in YUPELRI performance.

Completing enrollment in CYPRESS during the second half of 2024 and provide guidance on timing for top-line results as enrollment progresses.

Total Revenue

$10.4M

Previous year: $13.2M

-21.1%

EPS

-$0.24

Previous year: -$0.22

+9.1%